Patient Navigators for CKD and Kidney Failure: A Systematic Review

Taha, A S; Iman, Yasmin; Hingwala, Jay; Askin, Nicole; Mysore, Priyanka; Rigatto, Claudio; Bohm, Clara; Komenda, Paul; Tangri, Navdeep; Collister, David

doi:10.1016/j.xkme.2022.100540

Cited by 15 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They identified 16 health economic evaluation reports that compared dialysis modalities from both high-and low-income countries. Two similar review papers have also been published [15,16].…”

Section: Cost-effectiveness Of Renal Replacement Therapymentioning

confidence: 89%

Health Economics of Renal Replacement Therapy

Takura¹,

Ichimaru²,

Aikawa³

2024

Updates on Renal Replacement Therapy

View full text Add to dashboard Cite

The medical treatment of renal failure is increasingly being discussed in terms of medical economics against the background of disease mechanisms, treatment techniques, and related systems. Particularly, renal replacement therapy requires considerable medical resources and results in high medical costs; therefore, the interest in medical economics is increasing worldwide. This article discusses the cost-effectiveness of renal replacement therapy using macro- and micro-analyses. Based on the macroscopic analysis of international comparisons of renal replacement therapy systems based on medical expenses per patient with end-stage renal disease and a one-year mortality rate, Japan performed better than other developed countries. A clinical economic study of renal replacement therapy is significant because it quantitatively demonstrates the socioeconomic value of life-saving and health benefits (Hemodialysis: approximately 6.5 million JPY/Qaly). In other words, even with high annual medical expenses and a heavy financial burden, the level of medical fees is appropriate from the perspective of the public’s value judgment. A micro-analysis comparing the cost-effectiveness of marginal and standard donors revealed no statistically significant difference in their cumulative medical costs per long-term life expectancy. Thus, evidence and decision-making related to medical economics are required for the sustainable development of the medical system for end-stage renal disease.

show abstract

Section: Cost-effectiveness Of Renal Replacement Therapymentioning

confidence: 89%

Health Economics of Renal Replacement Therapy

Takura¹,

Ichimaru²,

Aikawa³

2024

Updates on Renal Replacement Therapy

View full text Add to dashboard Cite

show abstract

“…Collaborative care models must include patients, families, community groups, diverse health care professionals, health systems, government agencies and payers (Tuttle et al, 2022). Advocacy organizations and local community groups and peer navigators, having trusted voices and relationships, can be conduits for education and may provide input for development of patient tools and outreach programmes (Taha et al, 2022). Most importantly, patients must be at the centre of their care.…”

Section: Health Literacymentioning

confidence: 99%

Mind the gap in kidney care: Translating what we know into what we do

Luyckx,

Tuttle,

Abdellatif

et al. 2024

Journal of Renal Care

View full text Add to dashboard Cite

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

show abstract

“…The evidence around peer navigators (who may take a more active role than peer supporters in assisting recipients to access care and providing education) in CKD is less clear. A systematic review by Taha et al identified that the navigator role was more commonly performed by healthcare professionals than by peers (who were solely utilised in kidney transplantation care) [13]. The effectiveness of peer navigator programs to address racial inequities in kidney transplantation access will be assessed by an upcoming pragmatic randomised trial which will compare outcomes between peer navigation and kidney transplant fast track interventions in marginalised patients (Hispanic/Latino and American Indian) [14].…”

Section: Peer Supportmentioning

confidence: 99%

Multimodal approaches for inequality in kidney care: turning social determinants of health into opportunities

Purtell,

Bennett,

Bonner

2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of review Kidney disease is associated with major health and economic burdens worldwide, disproportionately carried by people in low and middle socio-demographic index quintile countries and in underprivileged communities. Social determinants such as education, income and living and working conditions strongly influence kidney health outcomes. This review synthesised recent research into multimodal interventions to promote kidney health equity that focus on the social determinants of health. Recent findings Inequity in kidney healthcare commonly arises from nationality, race, sex, food insecurity, healthcare access and environmental conditions, and affects kidney health outcomes such as chronic kidney disease progression, dialysis and transplant access, morbidity and mortality. Multimodal approaches to addressing this inequity were identified, targeted to: patients, families and caregivers (nutrition, peer support, financial status, patient education and employment); healthcare teams (workforce, healthcare clinician education); health systems (data coding, technology); communities (community engagement); and health policy (clinical guidelines, policy, environment and research). Summary The engagement of diverse patients, families, caregivers and communities in healthcare research and implementation, as well as clinical care delivery, is vital to counteracting the deleterious effects of social determinants of kidney health.

show abstract

Patient Navigators for CKD and Kidney Failure: A Systematic Review

Cited by 15 publications

References 43 publications

Health Economics of Renal Replacement Therapy

Health Economics of Renal Replacement Therapy

Mind the gap in kidney care: Translating what we know into what we do

Multimodal approaches for inequality in kidney care: turning social determinants of health into opportunities

Contact Info

Product

Resources

About